Immune Design Corp. (IMDZ) financial statements (2021 and earlier)

Company profile

Business Address 1616 EASTLAKE AVENUE E.
SEATTLE, WA 98102
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments961071201311416481
Cash and cash equivalents78697372722835
Short-term investments18394759693646
Restricted cash and investments    666
Receivables1110441
Inventory, net of allowances, customer advances and progress billings0111111
Inventory0111111
Prepaid expense2323221
Other current assets2      
Total current assets:1001121241351537790
Noncurrent Assets
Property, plant and equipment1011011
Deposits noncurrent assets00000  
Other noncurrent assets     11
Total noncurrent assets:1111111
TOTAL ASSETS:1011131251351547891
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities99869810
Accounts payable1333234
Accrued liabilities7654666
Estimated litigation liability    677
Deferred revenue and credits 00
Total current liabilities:9986151517
Noncurrent Liabilities
Liabilities, other than long-term debt0000000
Other liabilities0000000
Total noncurrent liabilities:0000000
Total liabilities:9986151517
Stockholders' equity
Stockholders' equity attributable to parent, including:921041171291396374
Additional paid in capital382381380378375286284
Accumulated other comprehensive loss(0)(0)(0)(0)(0)(0)(0)
Accumulated deficit(291)(277)(263)(249)(236)(224)(210)
Other undisclosed stockholders' equity attributable to parent0000000
Total stockholders' equity:921041171291396374
TOTAL LIABILITIES AND EQUITY:1011131251351547891

Income statement (P&L) ($ in millions)

12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
Revenues0011011
Revenue, net1011
Cost of revenue(1)(0)(0)(0)(0)(0)(0)
Cost of goods and services sold  (0)(0)(0)(0)(0)
Gross profit:(1)010011
Operating expenses(15)(15)(15)(14)(13)(14)(15)
Other undisclosed operating income1000000
Operating loss:(14)(15)(14)(14)(12)(14)(14)
Nonoperating income
(Other Nonoperating income)
1111000
Net loss available to common stockholders, diluted:(14)(14)(14)(13)(12)(13)(14)

Comprehensive Income ($ in millions)

12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
Net loss:(14)(14)(14)(13)(12)(13)(14)
Comprehensive loss:(14)(14)(14)(13)(12)(13)(14)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent000(0)(0)00
Comprehensive loss, net of tax, attributable to parent:(14)(14)(14)(13)(12)(13)(14)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: